For patients who undergo mastectomy, the margins must be histologically free of residual (microscopic or gross) tumor
Per the operative report, the gross total resection of the primary tumor with curative intent was completed within  weeks prior to randomization
Patients with gross total resection of the primary tumor prior to enrollment on ARST are NOT eligible; patients who have experienced tumor recurrence after a gross total tumor resection are NOT eligible
Primary surgical debulking before protocol therapy is permissible; this would include removal of gross symptomatic disease in the pelvis and/or vagina\r\n* Exenterative surgery is not permissible; patients with complete resection of gross recurrent disease are eligible
Patients who have gross residual disease or distant metastatic disease
Gross total resection (GTR) will be interpreted as modified Simpson grade - without gross residual dural-based or extradural tumor; GTR must be confirmed both by modified Simpson grade and by post-operative magnetic resonance imaging (MRI) findings
Status post gross total resection with curative intent
Any evidence of hematemesis, melena, hematochezia, ? grade  hemoptysis, or gross hematuria
Surgery achieves either no gross residual disease (R) or optimal cytoreductive status defined as no single lesion measuring more than . mm in its greatest diameter
Patients who undergo surgical resection will be allowed regardless of human papilloma virus (HPV) status provided they have one of the following criteria: \r\n* Positive margins on pathology\r\n* Evidence of extracapsular spread on nodal pathology\r\n* Gross residual disease on postoperative or simulation imaging\r\n* N/ disease\r\n* T/ disease\r\n* Multifocal perineural invasion and/or lymphovascular space invasion
The only surgical consideration is biopsy. Subjects who had gross total resection, partial resection and/or debulking are excluded.
Subjects who had gross total tumor resection, partial resection, and/or debulking surgery.
Participant has symptoms of gross hematuria or gross hemoptysis
Patients must have received no previous therapy for the tumor with the exception of corticosteroids and surgery; patients with a gross total resection will not be eligible
Gross total surgical resection with curative intent of the primary tumor and at least unilateral neck dissection within  weeks of registration
Have evidence of active clinically significant bleed (e.g., gastrointestinal bleed, hemoptysis, or gross hematuria) at screening
Uncontrolled cystitis, significant bladder pain or spasms, or gross hematuria that in the opinion of the treating investigator, should preclude study entry
Patients who have undergone a gross total resection for recurrence will be eligible, and MLA will be directed at treating a peritumoral margin of .- cm surrounding the resection cavity to disrupt the blood brain barrier (BBB) and potentially increase access of MK- to the peritumoral infiltrating glioma cells
Must have undergone gross total resection of the primary tumor with curative intent within the past  weeks with surgical pathology demonstrating >=  of the following criteria for \intermediate\ risk of recurrence:\r\n* Perineural invasion\r\n* Lymphovascular invasion\r\n* Single lymph node >  cm or at least  nodes without evidence of extracapsular extension\r\n* Close margins defined as <  mm but not frankly positive (in the case of ambiguous, controversial, or superseded margins, final clinical assessment regarding margin status will prevail)\r\n* Pathologically confirmed T or T primary tumor.
The primary tumor must be considered resectable by RP with gross negative margins as determined by a urologist. (Applicable to cohorts A and B only)
On-going gross hematuria associated with clots
Gross total excision of both the primary and nodal disease
The patient must be a candidate for surgical debulking (either subtotal or gross total resection); biopsy-only candidates will not be eligible
Patients must have undergone gross total surgical resection within  days prior to registration and beginning of therapy under the clinical trial. Note: Patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection.
Presence of metastatic disease or gross orbital involvement
No evidence of gross hematuria
Gross (visible) hematuria
Gross disease within the breast must be unifocal; (patients with microscopic multifocality are eligible as long as the total extent of tumor, gross and microscopic, occupies a volume with greatest dimension  cm or less)
Macroscopic complete salvage surgery with curative intent (surgery was not performed only for biopsy or palliation); final pathology and imaging must indicate a R or R resection (no gross disease remaining)
Any patient with gross residual disease following salvage surgery
Patients with gross residual tumor after surgical resection
COHORT II: Gross disease must be unifocal on Mammo/ MRI imaging
Current evidence of hematemesis, melena or gross hematuria
No gross vascular invasion or regional nodal or distant metastases
Presence of metastatic disease or gross (residual) orbital involvement
Patients will have no evidence of gross vascular invasion
The presence of gross skin invasion/ulceration by the breast cancer, or inflammatory changes with skin edema AND erythema; Note: Pagets disease is permitted
Patients who had craniotomy with biopsy, subtotal resection, total gross resection, or re-resection will be permitted.
Prior craniotomy and gross total or sub-total resection of tumor at this recurrence
Gross total or partial tumor resection is not possible or not planned
Patients with gross total resection of the primary tumor prior to enrollment are not eligible; patients who have experienced tumor recurrence after gross total tumor resection are not eligible
Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p negative), larynx, or hypopharynx squamous cell carcinoma (SCC) within  days prior to registration; note: patients may have a biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within  days prior to registration; if, however, patients have ablative resection but demonstrate rapid gross recurrence or are determined to have gross persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible
Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p negative), larynx, or hypopharynx within  days prior to registration; Note: patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within  days prior to registration; if, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible
Candidate for gross total or subtotal resection
Gross total excision of both primary and nodal disease with curative intent; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease; in other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessed
Previous radiosurgery to any currently progressive gross metastatic disease
Patients with multiple regional nodal basin involvement are eligible; gross or microscopic extracapsular nodal extension is permitted
Positive surgical margins are permitted if the surgeon confirms complete resection of gross metastatic disease, and post-operative scans are negative
Total (aggregate) gross tumor volume >  cm^ ( ccs or . liters)
Active untreated gross hematuria for any cause
Patients with gross residual or metastatic tumor findings following complete surgical treatment for uterine LMS
Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy; patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (IPMN) are eligible\r\n* The operating surgeon must document in the operative note that a complete gross excision of the primary tumor was achieved; the pathology report must include documentation of the margin status and the size of the tumor; the pathology report must also include the status of the three major marginsbile duct, pancreatic parenchyma, and retroperitoneal (uncinate)
Resected tumor: No evidence of gross tumor at the surgical resection margin noted in the final surgery report. No evidence of gross residual adenopathy
Patients who have had gross total excision of the primary tumor.
Patients who had craniotomy with biopsy, subtotal resection, total gross resection, or re-resection will be permitted
The tumor must be unifocal, confined to the supratentorial compartment and have undergone a gross total or near gross total resection; this will increase the likelihood that the patient will not require corticosteroids or develop pseudoprogression
Patients must have had all gross disease resected (R or R resection)
Not undergoing surgical resection or for whom gross total resection is not possible
Patient should have surgery (biopsy, partial resection or gross total resection) and no additional anti-cancer therapy except the chemoradiation as specified in the protocol
Achieved a gross total or sub-total resection at time of surgery
Gross residual tumor or positive margins after surgery that is un-excised, as radiation dose in the study will be limited to  Gy.
Gross total surgical resection with curative intent of the primary tumor and at least unilateral neck dissection within  weeks of registration
Evidence of clinically evident gross residual or recurrent disease following preoperative therapy and surgery
The patient must have undergone surgical resection (gross total, subtotal, or biopsy) of the spinal lesion(s) no more than  weeks prior to SRS treatment
Patient must not have gross residual and/or microscopic disease present after surgery including re-resection(s), per the operative and pathology report
Participants with gross hematuria are not eligible; patients with microscopic hematuria are eligible
Participants with gross hematuria are ineligible
Patients with more than  (i.e.,  or greater) uncontrolled or untreated extracranial sites of gross disease
Gross extension of tumor into the lumen of the duodenum
Subjects must have undergone primary gross total resection (no re-resected patients are allowed) with fulfillment of at least  of the following histologic criteria for high-risk disease:
Close (<mm) or positive surgical margins on microscopic evaluation with no gross residual tumor
Participants may have had a gross total resection, sub-total resection or biopsy\r\nonly
Patients who have undergone gross total resection and have no detectable residual disease are eligible
Gross total resection as determined by the intraoperative observations of the neurosurgeon of record and confirmed by postoperative MR imaging; gross total resection is defined as residual tumor or imaging abnormality (not definitive for residual tumor) whose size is <  cm^ on postoperative computed tomography (CT) or MR images
Histologic diagnosis of nodular desmoplastic medulloblastoma with less than gross total resection, but with no evidence of metastasis
Prior cancer treatment for this cancer, including gross total tumor excision
Concurrent febrile illness, urinary tract infection, or gross hematuria
Gross total resection followed by conventional chemoradiation therapy without progression of disease.
Patients with gross disease involving only the posterior elements
Patients with both pedicles involved with gross disease at the level of potential cement augmentation
Symptoms of gross hematuria or gross hemoptysis.
Patients with clinical evidence of gross disease
Gross nodal or metastatic disease at presentation (>= N, M)
The presence of gross skin invasion/ulceration by the breast cancer, or inflammatory changes with skin edema AND erythema; Note: Paget's disease is permitted
Patients with gross tumor involvement of the oral cavity or oral mucosa
Breast-conserving surgery with surgical excision of all gross disease with negative surgical margins (with the exception of a positive margin at skin and/or fascia where no more breast tissue can be removed) or mastectomy surgery with no gross residual disease
No gross disease visible on imaging at the start of radiotherapy
Definitive/gross total lesion resection
No gross disease visible on imaging at the start of radiotherapy
Subtotal, gross total or biopsy patients will be eligible
Gross tumor volume (GTV) or resection cavity must be visible on CT such that it can be delineated as a target for radiotherapy
